Ignite Creation Date:
2025-12-24 @ 3:04 PM
Ignite Modification Date:
2026-03-10 @ 8:37 PM
Study NCT ID:
NCT02023359
Status:
COMPLETED
Last Update Posted:
2015-12-29
First Post:
2013-12-23
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
Sponsor:
Novartis Healthcare A/S
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-12
Start Date Type:
None
Primary Completion Date:
2015-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-04
Completion Date Type:
ACTUAL
First Submit Date:
2013-12-23
First Submit QC Date:
None
Study First Post Date:
2013-12-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-12-26
Last Update Post Date:
2015-12-29
Last Update Post Date Type:
ESTIMATED